サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1138269

皮膚がんの世界市場-2022-2029

Global Skin Cancer Market - 2022-2029
出版日: | 発行: DataM Intelligence | ページ情報: 英文 180 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.70円
皮膚がんの世界市場-2022-2029
出版日: 2022年10月18日
発行: DataM Intelligence
ページ情報: 英文 180 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

市場力学

皮膚がんの世界市場の成長は、皮膚がんの発生件数の増加、オゾン層破壊につながる地球温暖化の進行、特に新興国における治療に対する意識の高まりに牽引されています。

皮膚がんの診断件数は増加しており、市場成長の原動力となることが期待されます。

米国における非黒色腫皮膚がんの診断と治療は、1994年から2020年の間に77％増加しました。非黒色腫皮膚がんの約90％は、紫外線（UV）に対する日光への曝露と関連しています。米国皮膚科学会では、米国では毎日約9,500人が皮膚がんと診断されています。2021年に米国で新たに診断されるメラノーマは196,060例、非浸潤性（in situ）は101,280例、浸潤性は106,110例と推定されます。浸潤性メラノーマは、2021年に男性（62,260例）、女性（43,850例）で5番目に多く診断されるがんと予測されます。非ヒスパニック系白人の皮膚がん発生率は、非ヒスパニック系黒人やアジア/太平洋諸島民の皮膚がん発生率の約30倍となっています。肌の色を持つ患者さんの皮膚がんは、治療が困難な後期段階で診断されることが多いのです。

アフリカ系アメリカ人のメラノーマ患者の25％は、がんが近くのリンパ節に転移した時点で診断されます。一方、16％は、がんが遠くのリンパ節や他の臓器に転移しているときに診断されます。手のひら、足の裏、足の付け根、口元など、日光にあまり当たらない部分に皮膚がんができやすいと言われています。また、爪の下にメラノーマができることもあります。皮膚がんの発生率は、50歳以前は男性より女性の方が高く、50歳以降は男性の方が高くなりますが、これはレクリエーションや仕事に関連した紫外線への露出の違いに関係していると思われます。調査によると、15歳から39歳の間にメラノーマと診断された男性は、同じ年齢層のメラノーマと診断された女性よりも死亡する確率が55%高いことが分かっています。したがって、皮膚がん診断の増加は、予測期間中の市場の成長を促進することになります。

皮膚がん診断の費用が高いことは、市場成長の妨げになると予想されます。

平均15万米ドルというがん治療費は、他の一般的な健康状態の治療費の4倍以上にもなります。疾病管理予防センター（CDC）によると、あらゆる種類の皮膚がんの治療には、少なくとも年間80億米ドルの費用がかかると推定されています。同機関は、メラノーマの新規患者の治療費は、2030年までに16億米ドルになると予測しています。したがって、これらの要因が予測期間中の市場の成長を妨げることになります。

産業分析

皮膚がん市場は、ポーターファイブフォース、アンメットニーズ、疫学、サプライチェーン分析など、様々な産業要因に基づく市場の詳細な分析を提供します。

セグメンテーション分析

非黒色腫セグメントは予測期間中（2022-2029年）に最も速いCAGRで成長すると予想されます。

非黒色腫皮膚がんは、通常、初期段階では単なる病変として扱われますが、適切に治療されないと、すぐに体の他の部位に転移する可能性があります。現在、世界では年間約200万人の非黒色腫皮膚がん、約13万2千人の黒色腫皮膚がんが発生しています。さらに、米国臨床腫瘍学会（ASCO）によると、2022年には、米国で330万人のうち年間540万人が基底細胞がんと扁平上皮がんと診断されると推定されています。1つ以上の皮膚がんと診断される方もいらっしゃいます。メラノーマ以外の皮膚がんの数は、数年前から増加しています。これは、病気の早期発見、日光への露出の増加、寿命の延長などが原因と思われます。基底細胞がんは、扁平上皮がんよりはるかに一般的です。メラノーマ以外の皮膚がんの約80％が基底細胞がんです。したがって、米国で最も一般的な悪性腫瘍であり、関連する罹患率とコストは相当なもので、死亡率は比較的小さいが重要なものです。非黒色腫皮膚がんの治療は、他の種類のがんと異なり、がんが体の他の部分に広がるリスクが著しく低いため、通常は成功します。メラノーマ以外の皮膚がんの治療は、約90％の症例で成功しています。したがって、メラノーマ以外の皮膚がんの発生率の増加と治療後の成功率が、予測期間中の市場の成長を牽引すると考えられます。

COVID-19の影響分析

COVID-19の大流行は、ヘルスケアシステムと皮膚がん市場に悪影響を及ぼしています。Cancer Connect 2020に掲載された記事によると、ダナファーバーがん研究所の医師は、COVID-19の流行期間中、皮膚がんを含む最も一般的な6種類のがんの診断が46％減少したことを明らかにしました。さらに、米疾病対策センター（CDC）や多くの医療専門機関は、がん検診などの健康予防サービスや、選択的手術はリスクが利益を上回らない限り延期し、COVID-19患者の治療のために病院のインフラを確保するよう勧告しました。このように、COVID-19の大流行が皮膚がん市場に影響を与えています。

世界の皮膚がん市場レポートでは、約45+市場データ表、40+図、180ページへのアクセスを提供します。

目次

第1章 調査手法と調査範囲

  • 調査手法
  • 調査目的および調査範囲

第2章 市場の定義と概要

第3章 エグゼクティブサマリー

  • 適応症タイプ別市場内訳
  • 治療法別の市場内訳
  • 診断別市場内訳
  • エンドユーザー別市場内訳
  • 地域別市場内訳

第4章 市場力学

  • 市場影響要因
    • 促進要因
      • 皮膚がん治療に対する認知度の向上
      • 皮膚がんの診断数の増加
    • 抑制要因
      • 皮膚がん診断の高コストが市場成長の妨げとなります。
    • ビジネスチャンス
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 規制分析

第6章 COVID-19の分析

  • COVID-19の市場分析
    • COVID-19以前の市場シナリオ
    • COVID-19の現在の市場シナリオ
    • COVID-19の後、または将来のシナリオ
  • COVID-19の中での価格ダイナミクス
  • 需要-供給スペクトラム
  • パンデミック時の市場に関連する政府の取り組み
  • メーカーの戦略的な取り組み
  • まとめ

第7章 適応症別

  • メラノーマ
  • 非黒色腫
    • 基底細胞がん
    • 扁平上皮がん
    • メルケル細胞がん

第8章 治療法別

  • 化学療法
  • 光線力学的療法
  • 免疫療法
  • 標的治療
  • 放射線療法
  • その他の治療法

第9章 診断別

  • 皮膚鏡検査
  • 皮膚生検
  • リンパ節生検
  • 画像検査
  • 血液検査
  • その他

第10章 エンドユーザー別

  • 病院
  • がん研究機関
  • その他

第11章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他の南米地域
  • アジア太平洋地域
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ地域

第12章 競合情勢

  • 主な展開と戦略
  • 企業シェア分析
  • 製品ベンチマーク
  • 注目すべき主要企業

第13章 企業プロファイル

  • Amgen, Inc.
    • 企業概要
    • 製品ポートフォリオと説明
    • 主なハイライト
    • 財務概要
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd
  • Merck & Co., Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Abbott Laboratories.
  • Sanofi SA
  • Novartis AG
  • Qiagen NV
  • Pfizer Inc.（*LIST NOT EXHAUSTIVE）

第14章 DataM

目次
Product Code: DMPH319

Market Overview

Skin Cancer Market is expected to grow at a CAGR 8% during the forecasting period (2022-2029). Skin cancer is the most common type of cancer caused due to abnormal growth of skin cells. It is estimated that 90% of skin cancer is caused majorly due to solar and artificial ultraviolet radiation (UV). Ultraviolet radiation is a primary carcinogen that results in UV-induced mutations, loss of activity in tumor suppressor genes, and the overexpression of oncogenes in keratinocytes, thus boosting the development of skin malignancies.

The Skin Cancer Market study analysis offers an in-depth outlook on the market containing both quantitative, and qualitative data. It gives an outlook and forecast of the global market based on the Skin Cancer Market segmentation by treatment type, and end user. It also provides Skin Cancer Market size, and growth, along with the latest trends, opportunities, and forecast till 2029 for the global Skin Cancer Market with esteem to major countries such as the United States, Canada, Brazil, Germany, Italy, Spain, United Kingdom, Russia, European countries, United Arab Emirates, Saudi Arabia, South Africa, Japan, China, India, South Korea, Australia, and rest of the countries over the globe.

Market Dynamics

The global skin cancer market growth is driven by the growing incidents of skin cancer, rise in global warming leading to depletion of ozone layer and increasing awareness about the treatment especially in the emerging nations.

The growing diagnosis of skin cancer is expected to drive market growth.

The diagnosis and treatment of nonmelanoma skin cancers in the U.S. increased by 77 percent between 1994 and 2020. About 90 percent of nonmelanoma skin cancers are associated with sun exposure to ultraviolet (UV) radiation. The American Academy of Dermatology Association, approximately 9,500 people in the U.S. are diagnosed with skin cancer daily. It is estimated that 196,060 new cases of melanoma, 101,280 noninvasive (in situ), and 106,110 invasives will be diagnosed in the U.S. in 2021. Invasive melanoma is projected to be the fifth most commonly diagnosed cancer for men (62,260 cases) and women (43,850 cases) in 2021. The incidence of skin cancer among non-Hispanic white individuals is almost 30 times higher than that among non-Hispanic Black or Asian/Pacific Islander individuals. Skin cancer in patients with skin color is often diagnosed in its later stages when it's more difficult to treat.

Twenty-five percent of melanoma cases in African American patients are diagnosed when cancer has spread to nearby lymph nodes. In contrast, 16% are diagnosed when cancer has spread to distant lymph nodes and other organs. People with skin color are prone to skin cancer in areas that aren't commonly exposed to the sun, like the palms of the hands, the soles of the feet, the groin and the mouth. They also may develop melanoma under their nails. Skin cancer rates are higher in women than in men before age 50 but are higher in men after age 50, which may be related to differences in recreation and work-related UV exposure. Research indicates that males diagnosed with melanoma between the ages of 15 and 39 are 55% more likely to die than females diagnosed with melanoma in the same age group. Thus, the growing skin cancer diagnosis will drive the market's growth in the forecast period.

The high cost of skin cancer diagnosis is expected to hamper the market growth.

At an average of $150,000, cancer treatment costs are more than four times higher than treatment for other common health conditions. As per the Centers for Disease Control and Prevention (CDC), it is estimated that treatment for all kinds of skin cancer costs at least $8 billion per year. The agency projects that the annual cost of treating new patients with melanoma will be $1.6 billion by 2030. Thus these factors will hamper the market's growth in the forecast period.

Industry Analysis

The skin cancer market provides in-depth analysis of the market based on various industry factors such as porter five forces, unmet needs, epidemiology, supply chain analysis etc.

Segmentation Analysis

The Non-melanoma segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

Non-melanoma skin cancer is usually treated as a simple lesion in the initial stages, but if not treated properly, it can quickly spread to other body parts. Currently, around 2-3 million non-melanoma skin cancers and 132,000 melanoma skin cancers occur globally yearly. Moreover, according to the American Society of Clinical Oncology (ASCO), in 2022, it is estimated that 5.4 million cases of basal cell carcinoma and squamous cell carcinoma will be diagnosed annually in the United States among 3.3 million people. Some people are diagnosed with more than 1 skin cancer. The number of non-melanoma skin cancers has been growing for several years. This is likely due to earlier detection of the disease, increased sun exposure, and longer life spans. Basal cell carcinoma is far more common than squamous cell carcinoma. About 80% of non-melanoma skin cancers are basal cell carcinoma. Thus, it is the most common malignancy in the United States, with substantial associated morbidity and cost and relatively small but significant mortality. Treatment for non-melanoma skin cancer is usually successful, as unlike the other types of cancer, there's a significantly lower risk of cancer spreading to other parts of the body. Treatment for non-melanoma skin cancer is successful in approximately 90% of cases. Hence, the increasing rates of non-melanoma skin cancer and its success rates after treatment will drive the market's growth in the forecast period.

Geographical Analysis

North American region holds the largest market share of the global skin cancer market.

In 2021, the North American region accounted for the largest market share. As per the American Academy of Dermatology, skin cancer is the most common cancer in the United States. Most cases of melanoma, the deadliest kind of skin cancer, are caused by exposure to ultraviolet (UV) light. It is estimated that approximately 9,500 people in the United States are diagnosed with skin cancer every day. Furthermore, according to the latest SEER data, melanoma is the fifth most common cancer diagnosis in the US (excluding non-melanoma skin cancers), with 106,000 estimated new cases in 2021, representing 5.6% of all cancer diagnoses. Thus, the increasing incidences of skin cancer in the region are a major factor driving the market growth.

Additionally, the recent advancements in skin cancer therapy, including photodynamic therapy (PDT), have been widely used in treating non-melanoma skin malignancies, thus driving the growth of the skin cancer market during the forecast period. For instance, Nanotechnology-based therapy is gaining popularity and becoming an essential topic to debate. Skin cancer nanotherapy is approached in a variety of ways and tactics. Nanoparticles targeting carcinoma cells, functionalized nanoparticles for specific targeting to cancer cells, receptor-mediated active targeting as nanoshells, nanostructured lipid carriers, liposome, ethosome, bilosome, polymeric nanoparticle, nanosphere, dendrimers, carbon nanotubes, quantum dots, solid lipid nanoparticles, and fullerenes that are highly efficient in the specific killing of cancer cells are all examples of strategic approaches.

COVID-19 Impact Analysis

The COVID-19 pandemic has negatively impacted healthcare systems and the skin cancer market. As per the article published in Cancer Connect 2020, doctors from Dana Farber Cancer Institute determined that during the COVID-19 pandemic, there was a 46% decrease in the diagnoses of the six most common cancer types, including skin cancer. Moreover, the Centers for Disease Control and Prevention (CDC) and many medical professional organizations recommended that cancer screening and other health prevention services, along with elective surgeries, be postponed unless the risks outweigh the benefits and secure the hospital infrastructure for the treatment of COVID-19 patients. Thus, the COVID-19 pandemic has impacted the skin cancer market.

Competitive Landscape

Major key players in the skin cancer market are Amgen, Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd, Merck & Co., Inc., Sun Pharmaceutical Industries Ltd., Abbott Laboratories., Sanofi SA, Novartis AG, Qiagen NV and Pfizer Inc. among others.

Amgen:

Overview:

Amgen is one of the world's leading biotechnology companies. It is engaged in pharmaceutical product research, development, and manufacturing. Amgen is a values-based company deeply rooted in science and innovation to transform new ideas and discoveries into medicines for patients with serious illnesses. The company offers a wide range of products for treating the central nervous system, neurosciences, ophthalmology, cancer, medical aesthetics, plastic surgery, dermatology, liver disease, inflammation, metabolic syndromes, and fibrosis. Amgen has 40 manufacturing facilities and 27 R&D, and Amgen, Inc is a biotechnology company that engages in the discovery, development, manufacture and marketing of human therapeutics and marketing facilities across the world.

­Product Portfolio:

IMLYGIC: IMLYGIC (talimogene laherparepvec) is a prescription medication used to treat a type of skin cancer called melanoma when it is on your skin or in your lymph glands.

The global skin cancer market report would provide an access to an approx. 45+market data table, 40+figures and 180pages

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

  • 3.1. Market Snippet By Indication Type
  • 3.2. Market snippet By Treatment
  • 3.3. Market snippet By Diagnosis
  • 3.4. Market Snippet by End User
  • 3.5. Market Snippet by Region

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing awareness about the treatment of skin cancer
      • 4.1.1.2. The growing diagnosis of skin cancer
    • 4.1.2. Restraints:
      • 4.1.2.1. High cost of skin cancer diagnosis will hamper the market growth
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Indication Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication Type Segment
    • 7.1.2. Market Attractiveness Index, By Indication Type Segment
  • 7.2. Melanoma*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2019-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Non-melanoma
    • 7.3.1. Basal cell carcinoma
    • 7.3.2. Squamous cell carcinoma.
    • 7.3.3. Merkel cell cancer

8. By Treatment

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 8.1.2. Market Attractiveness Index, By Treatment
  • 8.2. Chemotherapy*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2019-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Photodynamic Therapy
  • 8.4. Immunotherapy
  • 8.5. Targeted Therapy
  • 8.6. Radiation Therapy
  • 8.7. Other Treatments

9. By Diagnosis

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 9.1.2. Market Attractiveness Index, By Diagnosis Segment
  • 9.2. Dermatoscopy*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2019-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Skin Biopsy
  • 9.4. Lymph Node Biopsy
  • 9.5. Imaging Tests
  • 9.6. Blood Tests
  • 9.7. Others

10. By End User

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.1.2. Market Attractiveness Index, By End User Segment
  • 10.2. Hospital*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis, US$ Million, 2019-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 10.3. Cancer Research Institutes
  • 10.4. Others

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis, US$ Million, 2019-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication Type
    • 11.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 11.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 11.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 11.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication Type
    • 11.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 11.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 11.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 11.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. U.K.
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication Type
    • 11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication Type
    • 11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication Type
    • 11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

12. Competitive Landscape

  • 12.1. Key Developments and Strategies
  • 12.2. Company Share Analysis
  • 12.3. Product Benchmarking
  • 12.4. Key Companies to Watch

13. Company Profiles

  • 13.1. Amgen, Inc.*
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Key Highlights
    • 13.1.4. Financial Overview
  • 13.2. Bristol-Myers Squibb Company
  • 13.3. F. Hoffmann-La Roche Ltd
  • 13.4. Merck & Co., Inc.
  • 13.5. Sun Pharmaceutical Industries Ltd.
  • 13.6. Abbott Laboratories.
  • 13.7. Sanofi SA
  • 13.8. Novartis AG
  • 13.9. Qiagen NV
  • 13.10. Pfizer Inc.(*LIST NOT EXHAUSTIVE)

14. DataM Intelligence

  • 14.1. Appendix
  • 14.2. About Us and Services
  • 14.3. Contact Us